# Evommune, Inc.

**EVMN**

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0002044725


# None

### No letter

2 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $224.9M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data<br>not computable: dilution, short runway, distress, fortress balance sheet |
| **Inputs computable** | 2 of 14 |
| **Graded from** | filings received through Mar 5, 2026<br>251 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026 |
| **Last close** | $7.84<br>2026-11-10; market equity $284.7M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 5, 2026*

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria ("CSU"), atopic dermatitis ("AD") and ulcerative colitis ("UC"). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients' quality of life and leading to life-threatening conditions.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Accruals ratio | not computable | (6.6%) | | | | |
| *a prior annual assets observation is required* | | | | | | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 15.0** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *market price is missing at 2025-09-30* | | | | | | |
| Altman Z double-prime | 9.47 | (0.35) | | 9.5 | 745 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 8.57x | 2.95x | | 20.4 | 826 | 2025-12-31 |
| **Growth and financing** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four annual observations are required; found 1* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | | |
| *four consecutive annual FCF observations are required; found 1* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *a prior annual working-capital observation is required* | | | | | | |
| Asset growth, three years | not computable | 2.2% | | | | |
| *four annual observations are required; found 1* | | | | | | |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *two annual share counts are required; found 1* | | | | | | |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 2 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-10 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | not computable | (1.9%) | |
| Distance from 52-week high | (75.2%) | (28.5%) | 10 |
| EBIT to enterprise value | not computable | (1.6%) | |
| Free cash flow yield | (26.9%) | (1.0%) | 20 |
| Book value to price | 0.98 | 0.27 | 85 |
| Sales to price | 0.05 | 0.29 | 16 |
| Composite equity issuance, five years | not computable | 20.8% | |
| Relative strength against the sector, log excess return | not computable | (0.19) | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 97 (10-Q received Aug 6, 2026) |
| Median daily dollar volume, 63 sessions | $4.7M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$68.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$76.4M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 3 | assets | us-gaap:Assets | $224.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 4 | current assets | us-gaap:AssetsCurrent | $153.5M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 5 | current liabilities | us-gaap:LiabilitiesCurrent | $17.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 6 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$221.1M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 7 | operating income | us-gaap:OperatingIncomeLoss | -$81.1M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 8 | book equity | us-gaap:StockholdersEquity | $205.6M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 9 | liabilities | us-gaap:Liabilities | $19.4M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 10 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $13.0M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 11 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $235,000 | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 12 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $600,000 | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 13 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$68.9M | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 14 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-03-05 | 10-K | 26-093932 |
| 15 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 36,018,372 | 2026-03-03 | 2026-03-05 | 10-K | 26-093932 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.